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Pulse Pressure Amplification
A Mechanical Biomarker of Cardiovascular Risk
Athanase Benetos, MD,* Frédérique Thomas, MD,† Laure Joly, MD,* Jacques Blacher, MD, PHD,‡
Bruno Pannier, MD,† Carlos Labat, PHD,* Paolo Salvi, MD, PHD,* Harold Smulyan, MD,§
Michel E. Safar, MD‡
Nancy and Paris, France; and Syracuse, New York
Objectives The aim of this study was to determine whether the carotid/brachial (C/B) ratio is an independent predictor of
cardiovascular (CV) risk.
Background Brachial and carotid pulse pressure (PP) are independent predictors of CV risk, mainly in elderly patients. Be-
cause PP is physiologically lower at the brachial than at the carotid arterial site, PP amplification is represented
by the C/B ratio and could independently predict CV risk.
Methods In a Paris population (n  834), brachial and carotid PP were measured from sphygmomanometry and pulse
wave analysis. With stepwise multiple regression, carotid PP was calculated from a nomogram including age,
sex, body height, brachial PP, and plasma glucose. This model was applied to 125,151 subjects, followed for 12
years, during which 3,997 deaths occurred (735 of CV origin). With Cox regression analysis, multi-adjusted haz-
ard ratios (HRs) were calculated for 1 SD increase of brachial PP, calculated carotid PP, and C/B ratio.
Results Brachial PP was significantly associated with both CV and all-cause mortality (HR: 1.16, 95% confidence interval
[CI]: 1.13 to 1.19, and HR: 1.13, 95% CI: 1.10 to 1.17, respectively). Calculated carotid PP predicted a similar
risk (HR: 1.21, 95% CI: 1.15 to 1.28, and HR: 1.18, 95% CI: 1.12 to 1.25, respectively). Finally, the C/B ratio
was a strong risk predictor (HR: 1.22, 95% CI: 1.12 to 1.32, and HR: 1.41, 95% CI: 1.14 to 1.73, respectively).
Addition of drug treatment and other confounding variables did not statistically modify the results.
Conclusions Brachial PP, calculated carotid PP, and C/B PP amplification all predict CV mortality. In contrast to brachial and
carotid PP, the C/B ratio is less dependent on blood pressure calibration and thus can be directly applicable to
large population studies. (J Am Coll Cardiol 2010;55:1032–7) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.061b
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dhysiologically, central pulse pressure (PP) is lower than
rachial PP for the same mean blood pressure (MBP) and
iastolic blood pressure (DBP) (1–5). The difference be-
ween brachial and central PP, called PP amplification, is
pproximately 14 mm Hg (4,5) and might be expressed as
ither the difference or the ratio of these 2 pressures. Recent
tudies have shown that PP amplification (i.e., here the
arotid/brachial [C/B] ratio) might be a risk factor superior
o the values of brachial or central alone, particularly in
ubjects with advanced renal failure or with essential hyper-
ension and old age (1–3).
rom the *Department of Geriatrics CHU de Nancy, and INSERM U691,
niversity of Nancy, Nancy, France; †Centre d’Investigations Preventives et Clin-
ques, Paris, France; ‡Universite Paris Descartes; Assistance Publique-Hopitaux de
aris, Hôtel-Dieu, Centre de Diagnostic et de Thérapeutique, Paris, France; and the
Department of Medicine, Upstate Medical University, State University of New
ork, Syracuse, New York.h
Manuscript received April 8, 2009, revised manuscript received September 4, 2009,
ccepted September 7, 2009.For the same MBP and DBP, peripheral (brachial) PP
ecomes higher than central PP as the pulse passes through
rterial conduits that are characterized by progressive reduc-
ion in diameter and increased stiffness. Arterial wave
eflections from the periphery, however, exert the main
nfluence on PP amplification by augmenting the peripheral
ystolic blood pressure (SBP) more than the central SBP.
See page 1038
herefore, under physiological conditions, the pulsatile
urden is lower in central than in peripheral arteries, thus
rotecting the heart against excess load (4 – 6). With
ging, the cardiac load tends to increase, because of a
isproportional augmentation of central than brachial
rterial stiffness that raises central PP and thus reduces
eripheral PP augmentation (4). This process favors the
evelopment of cardiac hypertrophy and/or congestive
eart failure.
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March 9, 2010:1032–7 Pulse Pressure Amplification and CV RiskReduced pulse rate is associated with a retiming of central
ave reflections into systole due to the longer cardiac cycle
ength. The resulting higher central peak SBP reduces
mplification and increases cardiac work (4,6). By contrast,
n increased pulse rate significantly enhances carotid-
rachial amplification, a finding that is observed indepen-
ent of age (6). Therefore, PP amplification is due not only
o the propagation and reflection of pressure waves along
he arterial tree but also to the frequency dependence of
he corresponding transfer function (4,6). Finally, it has
een shown that there is a different effect of pulse rate
hanges on central and peripheral PP that depends upon
he arterial stiffness levels. In addition, the respective
ffect of pulse rate changes on wave reflection also depends
n arterial stiffness (7,8).
In recent years, it has been proposed that carotid PP
ould be directly measured with pulse wave analysis (4,6,9),
ut carotid PP also might be evaluated from appropriate
tepwise multiple regressions initiated from brachial PP
4,6,9–12). This procedure might be difficult to apply for
epeat determinations in individuals but is of major interest
or the development of inexpensive investigations in large
opulations with long-term follow-up.
The purpose of the present study was: 1) to develop a
oninvasive multiple regression analysis to calculate carotid PP
rom brachial PP measured with a simple standard sphygmo-
anometer; and 2) with this procedure, to evaluate the
redictive value of PP amplification on overall and cardiovas-
ular (CV) mortality in a large French population (4).
ethods
he present study described 2 different steps. The first step
nvolved a population in whom indirect noninvasive mea-
urements of carotid PP were obtained and subjected to a
ultiple regression analysis relating carotid PP (measured
y tonometry) with brachial PP (measured by sphygmoma-
ometry) and a series of hemodynamic, biochemical, and
tandard risk factors. The second step was to apply this
nalysis to a large French cohort, whose members were
ollowed for an average of 12 years, and study the impact of
rachial PP, calculated carotid PP, and PP amplification
C/B ratio) on all-cause and CV mortality.
irst step: evaluation of multiple regression analysis.
OPULATION DESCRIPTION. The studied population in-
luded 834 subjects referred to the Diagnosis Center of
roussais and/or Hôtel-Dieu hospital (Paris) for an evalu-
tion (check-up) ordered by their physician because of the
resence of CV risk factors and/or family history of CV
isease.
Patients with all forms of secondary hypertension, with
ancer, or with severe renal insufficiency (plasma creatinine
300 mol/l) were excluded from the study (10). Treated
ypertensive patients entered the study irrespective of their
P level. At inclusion, patients had a thorough review ofheir medical history for the detection of clinical events (nd/or signs related to the pres-
nce of CV risk factors. Venous
lood samples were obtained from
ll patients after an overnight fast
or routine biochemical investiga-
ions, including plasma total cho-
esterol, triglycerides, low-density
nd high-density lipoprotein cho-
esterol, and glucose and creatinine
evels, all determined by standard
ethods (3,10).
RACHIAL AND CENTRAL CAROTID
P MEASUREMENTS. All measure-
ents were performed in the
orning at stable room temper-
ture (20°C to 22°C), after an
vernight fast. Brachial BP determinations were performed
n the supine position after a 15-min rest in the laboratory
y traditional mercury sphygmomanometry, with the first
nd the fifth Korotkoff sounds for SBP and DBP measure-
ents, respectively. The average of the last 2 (of 3)
onsecutive BP measurements was used for data analysis.
For central BP determinations, radial artery and carotid
rtery applanation tonometry was applied with a high-fidelity
illar strain gauge transducer (SPT-301, Millar Instruments,
ouston, Texas) as described previously (3,4,6,10). Briefly, the
erived pressure waveforms were recorded on a Gould 8188
ecorder (Gould Electronic, Ballainvilliers, France) at a paper
peed of 100 mm/s. Radial artery pressure waveform calibrated
rom brachial artery SBP and DBP was used for determination
f peripheral MBP via application of an integration method.
ecause DBP and MBP differences throughout the arterial
ree are of minor value (ascending aorta to radial artery
ifferences do not exceed 2 to 3 mm Hg) (4,6,10–12), the
btained carotid BP wave was calibrated with brachial diastolic
nd radial mean BP. Mean BP of the carotid pressure wave-
orm, computed from the area method, was assumed to be
qual to peripheral mean BP to calculate the amplitude of the
arotid pressure waveform as well as carotid PP and SBP.
arotid PP was considered as a close surrogate of aortic PP.
his point has been previously validated with invasive mea-
urements as well as the use of mathematical transformation
4,6,9,10,13,14).
Reproducibility of all hemodynamic measurements has
een published in detail elsewhere, particularly regarding
arotid PP (10,12–14). The PP amplification between
arotid PP and brachial PP (mm Hg) was calculated as the
/B ratio. In the present population (n  834), the carotid
P measured by pulse wave analysis was compared with
arotid PP calculated from the multiple regression analysis
educed from the 834 studied patients (Tables 1 and 2).
econd step: mortality study. Subjects were examined at
he “Investigations Preventives et Cliniques” (IPC) Center
Abbreviations
and Acronyms
BP  blood pressure
C/B  carotid/brachial
CI  confidence interval
CV  cardiovascular
DBP  diastolic blood
pressure
HR  hazard ratio
MBP  mean (arterial)
blood pressure
PP  pulse pressure
SBP  systolic blood
pressureParis-France) (15). This medical center, which is subsi-
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Pulse Pressure Amplification and CV Risk March 9, 2010:1032–7ized by the French national health care system (Securite
ociale-CNAMTS), offers all working and retired individ-
als and their families a free medical examination every 5
ears. It is 1 of the largest medical centers of this kind in
rance, carrying out approximately 25,000 health examina-
ions/year for people living in the Paris area.
The IPC study population was composed of 72,437 (age
1.0  11.1 years) men and 52,714 (age 39.5  11.6 years)
omen who had a health checkup at the IPC Center
etween January 1981 and December 1988 (Table 3). To
ocus on primary prevention, subjects with previous CV
isease were excluded. Antihypertensive drug therapy in-
tep 1: Main Characteristics of the Population With Multiple RegreTable 1 Step 1: Main Characteristics of the Population With M
Men
(n  480
Age, yrs (min–max) 56.7 (15–9
Weight, kg 82.0 (13.1
Height, cm 174 (7)
BMI, kg/m2 27.1 (3.9)
Glycemia, g/l 1.12 (0.29
Creatinine, mg/l 10.5 (4.4)
Cholesterol, g/l 2.08 (0.37
Brachial SBP, mm Hg 142.5 (19.2
Brachial DBP, mm Hg 82.9 (12.7
Brachial MAP, mm Hg 102.8 (13.3
Brachial PP, mm Hg 59.5 (15.4
Pulse rate, beats/min 66.2 (11.0
Carotid PP, mm Hg 47.6 (14.9
C/B ratio 0.79 (0.10
Hypertensive subjects, % (n) 92.1 (442)
Antihypertensive treatment % (n)* 77.7 (373)
Current or former smokers, % (n) 59.8 (286)
Hypolipidemic treatment, % (n)† 12.2 (61)
Antidiabetic treatment, % (n)‡ 6 (29)
Subjects with aspirin or anti-inflammatory treatment, % (n) 18.3 (88)
alues are mean (SD) unless otherwise indicated. *28.9% with beta-blockers, 25.4% with angiote
BMI  body mass index; C/B  carotid/brachial; DBP  diastolic blood pressure; MAP  mean
arotid PP: Multiple Regression Analysis in Step 1Table 2 Carotid PP: Multiple Regression Analysis in Step 1
Parameters
Standard Regression
Coefficients (SEM) Partial R2 p Value
Intercept 0.064 (6.7)
Brachial PP, mm Hg 0.86 (0.02) 0.835 0.0001
Pulse rate, beats/min —
Height, m 6.62 (3.36) 0.0007 0.05
Glycemia, g/l 0.33 (0.15) 0.0001 0.03
HDL cholesterol, g/l —
Age, yrs 0.13 (0.02) 0.010 0.0001
Sex (M  1; F  2) 2.83 (0.62) 0.012 0.0001
Pulse wave velocity, m/s —
MBP, mm Hg —
DBP, mm Hg —
BMI, kg/m2 —
Model R2 0.858f
MI  body mass index; DBP  diastolic pulse pressure; HDL  high-density lipoprotein; MBP 
ean blood pressure; PP  pulse pressure.olved 4,499 patients (3.60%). The follow-up ending oc-
urred in 1998; during this period (mean duration: 12.1 
.2 years), 3,028 men and 969 women died. Among them,
00 men and 135 women died from CV disease. Measure-
ent methods have been described in detail elsewhere (15).
The IPC center received approval from the national
thical committee (Comite National d ‘Informatique et des
ibertes–CNIL) to conduct all these analyses. All subjects
ncluded gave their informed consent at the time of the
xamination. Mortality data were obtained from the mor-
ality records at the “Institut National de Statistiques et
’Etude Economiques” (INSEE), following a previously
stablished procedure (15).
tatistical analysis. In the first step, stepwise regressions
nalysis was carried out to evaluate the function estimating
arotid PP values. In the second step (epidemiological study),
he impact of brachial and carotid PP and PP amplification
C/B PP ratio or C/B ratio) on all-cause and CV mortality
ere evaluated with Cox regression models including age, sex,
eight and weight, and risk factors (smoking, physical activity,
holesterol, and diabetes mellitus). Because the C/B ratio is
nown to be highly influenced by pulse rate (4), models also
ncluded pulse rate as an adjusting factor. Hazard ratios (HRs)
ere calculated for each increase of 1 SD of brachial and
arotid PP and of the C/B ratio. All quantitative variables used
n the regression model or in the carotid PP equation were
onformed to a normality distribution, and colinearity
ssessments were taken into account in multivariate analysis.
ll statistical analyses, including interactions, were per-
Analysisle Regression Analysis
Women
(n  354)
All
(n  834)
p Value
(Men vs. Women)
57.9 (21–91) 57.2 (15–91) 0.23
68.1 (13.3) 76.1 (14.9) 0.0001
161 (7) 168 (9) 0.0001
26.2 (5.1) 26.8 (4.5) 0.003
1.07 (0.29) 1.10 (0.28) 0.06
7.66 (2.8) 9.3 (4.0) 0.0001
2.13 (0.46) 2.10 (0.42) 0.08
141.0 (21.1) 141.9 (20.1) NS
79.4 (11.5) 81.4 (12.3) 0.0001
100.0 (12.6) 101.6 (13.1) 0.002
61.6 (18.9) 60.4 (17.0) 0.09
68.0 (10.6) 67.0 (10.8) 0.01
52.9 (18.3) 49.9 (16.7) 0.0001
0.86 (0.12) 0.82 (0.11) 0.0001
93.8 (332) 92.8 (774) NS
74.3 (263) 76.3 (678) NS
33.6 (119) 48.6 (405) 0.0001
11.6 (41) 12.2 (102) NS
7.1 (25) 6.5 (54) NS
15.0 (53) 16.9 (141) NS
ockade, 45.7% with calcium blockade. †Fibrate or statin. ‡Insulin and/or oral administration.
l pressure; NS  not significant; PP  pulse pressure; SBP  systolic blood pressure.ssionultip
)
0)
)
)
)
)
)
)
)
)
)
)ormed with the version 8.2 of the SAS statistical software
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March 9, 2010:1032–7 Pulse Pressure Amplification and CV RiskSAS Institute, Cary, North Carolina). A p value0.05 was
onsidered significant.
esults
tep 1: models of carotid PP evaluation. The main
linical and biological characteristics of the population
n  834) are listed in Table 1. In bivariate analysis, carotid
P was closely correlated with brachial PP (r  0.916, p 
.0001). Table 2 reports the results of stepwise regression
nalysis in this population. The major components of total
ariance were represented by the following parameters:
rachial PP, plasma glucose, body height, age, and sex.
rug treatment, pulse rate, MBP, DBP, and body mass
ndex had no statistical significance in the stepwise regres-
ion. The model established in the population explained
6% of carotid PP variance and was then used for the
pidemiological study.
tep 2: epidemiological study. Table 3 represents the
haracteristics of the IPC population according to sex.
igure 1 shows the mean values of carotid and brachial PP
ccording to age. Both PP values increase with age, but the
/B ratio trends toward 100%, because carotid PP increases
ore rapidly than brachial PP with age.
Table 4 shows the values of HR for CV and all-cause
ortality when included in the model for brachial PP or
arotid PP after adjusting for age, sex, traditional CV risk
actors, and pulse rate. Both brachial and carotid PP were
ignificant and to a similar extent predictors of CV and
ll-cause mortality: for brachial PP, HRs were 1.16 (95%
onfidence interval [CI]: 1.13 to 1.19) and 1.13 (95% CI:
Step 2: Main Characteristics of the IPC PopulatTable 3 Step 2: Main Characteristics of the
Age, yrs (min–max)
Weight, kg
Height, cm
BMI, kg/m2
Plasma glycemia, g/l
Plasma creatinine, mg/l
Plasma cholesterol, g/l
Brachial SBP, mm Hg
Brachial DBP, mm Hg
Brachial MAP, mm Hg
Brachial PP, mm Hg
Pulse rate, beats/min
Carotid PP, mm Hg
C/B ratio
Hypertensive subjects, % (n)
Antihypertensive treatment, % (n)*
Current smokers, % (n)
Subjects with aspirin treatment or anti-inflammatory agent,
Values are mean (SD) unless otherwise indicated. *With or without an
Abbreviations in Table 1..10 to 1.17), respectively; for carotid PP, HRs were 1.2195% CI: 1.15 to 1.28) and 1.18 (95% CI: 1.12 to 1.25),
espectively. Carotid HRs were slightly but constantly
igher than brachial HR. Finally, the C/B ratio PP was also
trongly predictive of prognosis (respective HRs: 1.22 [95%
I: 1.12 to 1.32] and 1.41 [95% CI: 1.14 to 1.73], for 1 SD
ncrease). Further adjustment for drug treatment did not
ignificantly change the results (Table 4, lower panel). A
eparate analysis in diabetic and nondiabetic subjects
howed similar results in these groups and no interaction
data not shown).
iscussion
n this study, we used a population of outpatients in whom
e simultaneously and noninvasively measured brachial and
arotid PP. For this, we established a multiple regression
ccording to SexPopulation According to Sex
Men
(n  72,437)
Women
(n  52,714)
All
(n  125,151)
41.0 (16–95) 39.5 (16–95) 40.4 (16–95)
73.9 (10.7) 58.5 (9.6) 67.4 (12.7)
173.8 (6.8) 162.0 (6.0) 168.3 (9.2)
24.5 (3.2) 22.7 (3.6) 23.7 (3.5)
1.03 (0.13) 0.97 (0.10) 1.00 (0.13)
10.44 (1.28) 8.49 (1.18) 9.62 (1.24)
2.19 (0.45) 2.07 (0.42) 2.14 (0.44)
134.0 (13.6) 128.3 (14.2) 132.1 (14.3)
82.9 (10.1) 78.3 (10.1) 81.0 (10.3)
100.3 (10.7) 95.0 (10.8) 98.0 (10.7)
52.0 (8.6) 49.9 (8.7) 51.1 (8.7)
69.4 (12.8) 73.2 (10.3) 71.0 (12.0)
39.2 (7.6) 40.7 (7.9) 39.8 (7.8)
0.79 (0.03) 0.85 (0.03) 0.82 (0.42)
45.6 (33,025) 26.9 (14,184) 37.8 (47,209)
3.35 (2,426) 3.94 (2,073) 3.60 (4,499)
33.8 (24,507) 23.5 (12,372) 29.5 (36,879)
8.1 (5,869) 14.8 (7,786) 10.9 (13,655)
tic or hypolipidemic agent.
Figure 1 Step 2: Brachial PP, Carotid PP,
and the C/B Ratio According to Age
Brachial pulse pressure (PP) (mm Hg) (diamonds), carotid PP (mm Hg)
(squares), and the carotid/brachial (C/B) ratio (%) (triangles) according to age.ion AIPC
% (n)
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Pulse Pressure Amplification and CV Risk March 9, 2010:1032–7nalysis that permitted calculation of carotid PP from
rachial PP while adjusting for age, sex, body height, and
lasma glucose but not MBP, DBP, pulse rate, or drug
reatment (Table 2). The variance explained by the corre-
ponding stepwise multiple regression approximated 86%.
he methodology of brachial PP measurement and of
arotid PP calculation was applied to the large epidemio-
ogical IPC cohort. Both carotid and brachial PP had a
ignificant predictive value on overall and CV mortality
isks, independently of CV risk factors. Finally, PP ampli-
cation, expressed as the C/B ratio, was strongly associated
ith both CV and overall mortality risks, with the highest
Rs. Thus, after adjustment for age, sex, associated risk
actors, and presence of antihypertensive treatment, an increase
f 1 SD of PP amplification was associated with an increase of
9% of the all-cause mortality and of 30% of the CV mortality.
ll results were independent of any other confounding factors
ncluding pulse rate and drug treatment.
The methodological basis of the present study was to
etermine the ratio between the carotid and brachial artery
P with a validated tonometric sensor. This previously
escribed methodology (4,16) requires at least 3 major
rerequisites. First, high-quality radial artery and carotid
rtery BP curves should be recorded transcutaneously. Sec-
nd, after calibration of the curves with the brachial artery
uscultatory method, the radial and carotid curves should be
onsidered to have the same mean BP determined by
lanimetry. Third, the difference between MBP and DBP
easured at the brachial and carotid arterial sites are
onsidered to be nearly identical and both of small ampli-
ude (4,16). Finally, carotid SBP can then be deduced from
he calibrated carotid BP curve and is potentially corrected
rom the small arterial amplification (5 mm Hg) observed
etween the brachial and the radial arteries (17). Noninva-
ive and invasive methods have in the past extensively
alidated this methodology and showed that BP measured
t the carotid arterial site varied in strict parallelism with
horacic aorta or carotid BP measured with a transfer
djusted Risk of All-Cause Mortality and CVortality A sociated With the Increase of 1 SD ofrachial PP, Caro id PP, and C/B R tio
Table 4
Adjust Ri k of All-Cause Mortality and CV
Mortality Associated With the Increase of 1 SD of
Brachial PP, Carotid PP, and C/B Ratio
All-Cause Mortality CV Mortality
Upper panel
Brachial PP HR 1: 1.13 (1.10–1.17) HR 1: 1.16 (1.13–1.19)
Carotid PP HR 2: 1.18 (1.12–1.25) HR 2: 1.21 (1.15–1.28)
C/B ratio HR 3: 1.22 (1.12–1.32) HR 3: 1.41 (1.14–1.73)
Lower panel
Brachial PP HR 1: 1.13 (1.12–1.15) HR 1: 1.17 (1.15–1.19)
Carotid PP HR 2: 1.17 (1.14–1.20) HR 2: 1.20 (1.13–1.27)
C/B ratio HR 3: 1.19 (1.12–1.27) HR 3: 1.30 (1.12–1.52)
djusted risk of all-cause mortality and cardiovascular (CV) mortality (hazard ratio [HR] and 95%
onfidence interval) associated with the increase of 1 SD of brachial pulse pressure (PP), carotid
P, and carotid/brachial (C/B) ratio. Upper panel: adjustments were made for age, sex, smoking,
hysical activity, cholesterol, diabetes mellitus, and pulse rate. Lower panel: adjustments as upper
anel plus antihypertensive treatment.unction (4,14,16). fThe major limitation of this methodology is related to the
alibration of the carotid BP curve, which requires the use
f the classical transcutaneous auscultatory method to measure
he brachial artery SBP and DBP (16). With this procedure,
he determination of SBP is known to be quite adequate in
ontrast with the determination of DBP (4,14). The DBP
rror is somewhat attenuated, because DBP is identical in all
arts of the arterial tree. This observation minimizes the
ifficulties introduced by using peripheral DBP to estimate
entral DBP measurements. When PP amplification is
alculated as the C/B ratio, this ratio becomes independent
f brachial artery calibration (expressed in voltage) and is
nfluenced only by the reliability of detection of the brachial
ressure pulse by the auscultatory method and the method-
logy used to estimate the central aortic or carotid pulse
17). This procedure undoubtedly facilitates the compari-
ons of BP measurements between various laboratories and
nder different circumstances.
An important advantage of the present study results from
he use of stepwise multiple regression model, which asso-
iates hemodynamic and biological parameters with a very
igh proportion of variance explained (86%). This method
ight then be used to better advantage for large inexpensive
tatistical evaluations than for repeated determinations in
ndividuals. The major component of this variance is bra-
hial PP, representing more than 80% of the variance, as
reviously reported and validated in the published data
6,12,16,18–20). The remaining components exclude the
nfluence of other major factors, such as drug treatment,
BP, DBP, and body mass index, but also involve age, sex,
nd height, but among the standard CV risk factors, only
lasma glucose.
The major finding of this study was to show that: 1) when
rachial and carotid PP are used separately to evaluate
djusted CV risk, each of them have a consistent impact;
ut 2) when the C/B ratio is calculated in the same
opulation, the HR of this ratio is greater by comparison
han that obtained from each of its brachial or carotid
omponents— especially with regard to CV mortality
Table 4). As shown earlier, the increase in PP from
entral to peripheral arteries physiologically contributes
o reduce the cardiac pulsatile load. Aging increases
entral more than brachial PP, leading to an increase in
he C/B ratio.
rospective views. This study has proposed a method to
alculate, in humans, central (carotid) PP from measured
rachial PP and to deduce CV risk from the ratio
etween the 2 variables. An epidemiological study involv-
ng 125,151 subjects indicates that the C/B ratio is a
owerful risk predictor. The ratio is poorly influenced by
he calibration used for the BP curve measurements.
onsequences in CV risk reduction strategies and titra-
ion of antihypertensive drug treatment remain yet to be
urther established.
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